sonelokimab
Antibody-derived scaffold
Also known as ALX-0761
Evidence outlook · lead readout
IZAR-1 (NCT06641076) · Arthritis, Psoriatic
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
IZAR-1 (NCT06641076): This was a randomized, triple-masked Phase 3 trial with 960 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-08-10. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Also in development:Hidradenitis Suppurativa · Phase 3
Company guidance: topline data expected Q1 2027 (NCT06641089; MoonLake Immunotherapeutics, 4 Nov 2026). “Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol” Source ↗
Company guidance: data expected early 2027 (MoonLake Immunotherapeutics, 4 Nov 2026). “In addition, we expect results of the P-OLARIS trial (M1095-snSpA-202) to become available in early 2027.” Source ↗
Company guidance: topline data expected H1 2027 (MoonLake Immunotherapeutics, 10 Aug 2026). “IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027 whereas the IZAR-2 trial” Source ↗
Company guidance: topline data expected Q2 2027 (NCT06641076; MoonLake Immunotherapeutics, 4 Nov 2026). “PsA: IZAR-1: Expected to announce Week 52 topline results in Q2 2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
IZAR-1 NCT06641076 · Arthritis, Psoriatic This was a randomized, triple-masked Phase 3 trial with 960 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-08-10. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate. Registry: NCT06641076 | 3 | Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) (Week 16) 2026-05-28 | Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). | Partial signal | link ↗ |
View 2 more trials
IZAR-2 NCT06641089 · Arthritis, Psoriatic Registry: NCT06641089 | 3 | Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) (Week 16 compared to placebo) 2027-01-04 | In progress: results expected 4 Jan 2027 | not yet graded | link ↗ |
NCT05640245 NCT05640245 · Arthritis, Psoriatic The study randomized 207 participants and used triple blinding with both placebo and active adalimumab comparator arms. Its primary endpoint was the clinical ACR50 response at week 12. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05640245 | 2 | Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) (Week 12) 2023-09-05 | ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other IL-17A/F drugs
bimekizumab, Lecankitug, ORKA-002. Compare all 4 IL-17A/F drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Hidradenitis Suppurativa: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sonelokimab: this drug | Phase 3 | Antibody-derived scaffold | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Partial signal | NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Partial signal | NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants | |
| Lutikizumab | Phase 3 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2/3 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Spesolimab (Spevigo) | Phase 2/3 | Monoclonal antibody | IL-36 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Abdakibart | Phase 2 | Monoclonal antibody | IL-1 beta | not yet graded | No reviewed efficacy summary in this indication | |
| Duvakitug | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Eltrekibart | Phase 2 | Monoclonal antibody | CXCR1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ORKA-002 | Phase 2 | Monoclonal antibody | IL-17A/F | not yet graded | No reviewed efficacy summary in this indication | |
| SAR442970 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SAR445399 | Phase 2 | Monoclonal antibody | IL-1R3 (IL1RAP) | not yet graded | No reviewed efficacy summary in this indication | |
| SPY072 | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| Zasocitinib | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1451 | Phase 1(overall) | Undisclosed | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| SAR447971 | Phase 1(overall) | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipasertideg | Discontinued | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow sonelokimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
Company guidance: topline data expected Q1 2027 (MoonLake Immunotherapeutics, 4 Nov 2026). “Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol” Source ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent